Matrine inhibits the invasive and migratory properties of human hepatocellular carcinoma by regulating epithelial-mesenchymal transition

YUWEN WANG¹,²*, SHUJUN ZHANG³, JIA LIU², BIAOBIAO FANG², JIE YAO² and BINGLIN CHENG²

¹Shenzhen Longhua District Central Hospital, Shenzhen, Guangdong 518110; ²Department of Traditional Chinese Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150000; ³Department of Pathology, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China

Received February 25, 2017; Accepted April 13, 2018
DOI: 10.3892/mmr.2018.9023

Abstract. Matrine has been reported to be an effective anti-tumor therapy; however, the anti-metastatic effects of matrine on hepatocellular carcinoma (HCC) and the molecular mechanism(s) involved remain unclear. Therefore, the aims of the present study were to evaluate the effects of matrine on hepatoma and to determine the associated mechanism(s) involved. In the present study, matrine was confirmed to prevent the proliferation of HCC cells and it was observed that matrine also inhibited the migratory, and invasive capabilities of HCC at non-toxic concentrations. Additionally, matrine increased epithelial-cadherin expression and decreased the expression levels of vimentin, matrix metalloproteinase (MMP) 2, MMP9, zinc finger protein SNAI1 and zinc finger protein SNAI2. These results indicate that the anti-metastatic effect of matrine may be associated with epithelial-mesenchymal transition (EMT). Furthermore, matrine can increase phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN (PTEN) expression and reduce phosphorylated-protein kinase B (Akt) levels. In conclusion, these results suggested that matrine is a potential therapeutic agent that can suppress cancer-associated invasion and migration via PTEN/Akt-dependent inhibition of EMT.

Introduction

Hepatocellular carcinoma (HCC) is the most frequently occurring primary cancer of the liver and is the 5th, and the 3rd leading cause of cancer-associated death worldwide among women and men, respectively (1). These poor outcomes result from its high recurrence following liver resection and its resistance to systemic chemotherapy (2,3). As cases of HCC are frequently identified at advanced stages of the disease, these patients are only eligible for palliative care. Furthermore, as no effective palliative chemotherapies are available, the prognosis of patients with advanced HCC is poor (4). Therefore, developing pharmacologically effective agents from natural products with minimal toxicity or minimal adverse effects has become an area of interest.

Epithelial-mesenchymal transition (EMT), the process by which epithelial cancer cells lose their polarity and become motile mesenchymal cells, has been implicated in carcinoma invasion and metastasis (5). Downregulation of epithelial (E)-cadherin and the acquisition of mesenchymal markers including vimentin, are regarded as the key steps of EMT. The zinc-finger proteins Snail (Snail) and SNAI2 (Slug) are the most prominent suppressors of E-cadherin transcription (6,7). Matrix metalloproteinases (MMPs) are a family of metalloendopeptidase that cleave the protein components of the extracellular matrix (ECM) and the endothelial cell basement membrane (8). MMPs serve a central role in tumor EMT by the cleavage of components of the ECM and the endothelial cell basement membrane. MMP2 and MMP9, members of the MMP family, have been demonstrated in cancer tissues, and are associated with the processes of tumor aggression, and metastasis in human cancer (9). Furthermore, a previous study reported that MMP2 and MMP9 could break down cell surface associated molecules (10), and could cleave the E-cadherin ectodomain near the plasma membrane into soluble E-cadherin (11), which may be involved in MMPs-enhanced invasion and metastatic potential of cancer cells.

Matrine is an essential compound identified in the traditional Chinese herb Sophora flavescens Ait. (12), which has been used to treat viral hepatitis, liver cirrhosis, cardiac arrhythmia and skin inflammations in China for centuries; furthermore,
this herb does not exhibit any obvious side-effects (13). Previously findings revealed that matrine exerts anti-tumor effects on several tumor cell types, including HCC, as well as pancreatic, gastric and breast cancer. In addition, matrine was demonstrated to enhance the immune function of patients and therefore improve the quality of life of patients (14). Although matrine has been used clinically to treat various types of cancer in recent years, the therapeutic efficacy of matrine for EMT of HCC remains poorly understood.

Consistent with the published literature, the present study aimed to ascertain whether there were any alterations in EMT in hepatoma cells as a result of being treated with matrine, to investigate the mechanisms underlying the diminished EMT activity of matrine through the phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN (PTEN)/protein kinase B (Akt) signaling pathway and altered the expression of proteins involved in EMT, including MMP2, MMP9, E-cadherin, vimentin, Slug and Snail. The aim of the present study was to develop novel strategies for the treatment of HCC.

Materials and methods

Chemicals and reagents. Matrine (purity >98%), MTT, Triton X-100 and dimethyl sulfoxide (DMSO) were all purchased from Sigma-Aldrich (Merck KGaA, Darmstadt, Germany). Anti-phosphorylated (p)-Akt (cat. no. 66444-1-lg), anti-Akt (cat. no. 55230-1-AP), anti-PTEN (cat. no. 22034-1-AP), anti-E-cadherin (cat. no. 20874-1-AP) and anti-vimentin (cat. no. 10366-1-AP) antibodies were all purchased from Wuhan Sanying Biotechnology (Wuhan, China). Anti-MMP2 (cat. no. 40994), anti-MMP9 (cat. no. 3852), anti-Snail (cat. no. 3879), anti-Slug (cat. no. 9585) antibodies and DyLight™ 594 Phalloidin (cat. no. 12877) were all purchased from Cell Signaling Technology, Inc. (Danvers, MA, USA). The anti-β-actin (cat. no. TA-09) antibody was purchased from OriGene Technologies, Inc. (Beijing, China). Radio immunoprecipitation assay (RIPA) lysis buffer and DAPI staining solution were purchased from the Beyotime Institute of Biotechnology (Shanghai, China).

Cell culture. Fetal bovine serum (FBS), penicillin/streptomycin and trypsin were all purchased from Gibco (Thermo Fisher Scientific, Inc., Waltham, MA, USA). Dulbecco's modified Eagle's medium (DMEM) was purchased from Invitrogen (Thermo Fisher Scientific, Inc.). The human hepatoma cell line Huh-7 was purchased from the Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Science (Shanghai, China). Huh-7 cells were cultured in DMEM supplemented with 100 U/ml penicillin, 100 µg/ml streptomycin and 10% FBS and incubated at 37°C in a humidified atmosphere containing 5% CO2.

Cell viability assays. The MTT assay was used to assess the cytotoxic activity of matrine. Huh-7 cells were plated in 96-well culture plates (1x104 cells/well) and allowed to adhere overnight at room temperature, following which the cells were treated with various concentrations of matrine (0, 0.2, 0.4, 0.8, 1.0, 1.2, 1.4, 1.6, 1.8, or 2.0 mg/ml). The cells were subsequently incubated for 24 and 48 h then they were washed twice with PBS and treated with 5 mg/ml MTT for 4 h. The cells were washed with PBS and then solubilized with 150 µl DMSO. The optical density values were measured at an absorbance of 490 nm using a Wellscan reader (Thermo Labsystems, Santa Rosa, CA, USA). The percentage inhibition of cellular proliferation was calculated using equation ‘the inhibitory percentage (%) = [1 - A490(test)/A490(blank)] x100%’. The assays were performed in triplicate in three independent experiments.

Colony forming assay. Huh-7 cells in the exponential growth phase were seeded into 6-well plates at a density of 8x104 cells/well. Following incubation of the cells for 12 h, they were treated with 0, 0.8, or 1.6 mg/ml matrine for 24 h and then continuously cultured in fresh medium at 37°C in a humidified atmosphere containing 5% CO2. Following 10-15 days of culture, the cells were first washed twice with PBS, then fixed with methanol for 30 min at room temperature and finally stained with 0.5% crystal violet for 30 min at room temperature. A colony was defined as a unit of at least 50 cells and all visible colonies were counted by light microscopy. The colony formation rate was reported as a percentage and calculated as the number of colonies/the number of seeded cells x100. The assays were performed in triplicate in three independent experiments.

Wound healing assays. For the wound healing assays, Huh-7 cells were seeded in 6-well plates at a density of 2x104 cells/well and cultured for 24 h. Wounds were scratched with a 10 µl pipette tip and then PBS was used to wash the wells and remove floating cells prior to the addition of serum-free medium. The cells were then treated with 0, 0.2, 0.4 or 0.8 mg/ml matrine for 0, 12 and 24 h. The migratory distance of the cells was measured and analyzed using ImageJ 1.48 version (National Institutes of Health, Bethesda, MD, USA). The tests were performed in triplicate in three independent experiments.

In vitro invasion and migration assays. Cell migration and invasion assays were performed using Transwell chambers with 8-µm pores (Corning, Incorporated, Corning, NY, USA). Huh-7 cells were pretreated with 0, 0.2, 0.4 or 0.8 mg/ml matrine for 24 h. For the migration assay, 1x104 cells/well in serum-free medium were seeded in the upper chamber on a non-coated membrane. The lower chamber was filled with medium containing 20% FBS, whereas the upper chamber with a membrane pre-coated with Matrigel (BD Biosciences, Franklin Lakes, NJ, USA) were used for the invasion assay. The cells were subsequently incubated for 24 h at 37°C, those on the upper side of the inserts were removed by swabbing with a cotton swab and the cells on the bottom side of the filter were fixed with 100% methanol for 30 min at room temperature and stained with 0.5% crystal violet for 30 min at room temperature. The cells on the lower surface were then counted and images were captured under an inverted light microscope (Olympus Corporation, Tokyo, Japan). The assays were performed in triplicate in three independent experiments.

Immunofluorescence. Huh-7 cells were plated onto chamber slides at 2x104 cells per chamber for 12 h and stimulated with 0 and 0.8 mg/ml matrine for 24 h. Then, the cells were fixed
with 4% paraformaldehyde for 30 min at room temperature and subsequently permeabilized with 0.25% Triton X-100 for 20 min at room temperature. The slides were then treated with 0.5% bovine serum albumin (BSA; Beyotime Institute of Biotechnology, Jiangsu, China) in 0.1% Tween-20 for 30 min at room temperature, primary antibodies targeting E-cadherin and vimentin were added at a 1:1,000 dilution and incubated on the slides overnight at 4°C. Secondary antibodies conjugated with the green fluorescent Alexa Fluor 594 dye (FITC Conjugated Goat Anti-Rabbit IgG; cat. no. TA130021), were purchased from OriGene Technologies, Inc. (Rockville, MD, USA), were added to the slides at a dilution of 1:1,000 for 1 h at room temperature. Then, the cells were washed with PBS and the coverslips were mounted using an anti-fade mounting solution containing DAPI prior to imaging the cells for 10 min at room temperature. The projected cell area was evaluated using ImageJ software. The assays were performed in triplicate in three independent experiments.

Western blot analysis. Huh-7 cells were planted in 6-well plates at 2x10⁶ cells per well, treated with different concentrations of matrine (0, 0.2, 0.4, or 0.8 mg/ml) for 36 h and then lysed using a RIPA buffer. The lysates were centrifuged at 4°C at 12,000 x g for 15 min and the protein concentration of the remaining supernatants was measured using a bicinchoninic protein assay kit (Beyotime Institute of Biotechnology). Samples of total protein (20 µg) were separated using 12% SDS-PAGE. The separated proteins were then transferred to polyvinylidene difluoride membranes (EMD Millipore, Billerica, MA, USA) at 0.8 mA/cm² for 2 h. Following blocking of these membranes with a solution of 5% non-fat dry milk in buffer at 37°C for 1 h, they were treated with antibodies targeting E-cadherin, vimentin, Slug, Snail, PTEN, Akt, p-Akt and β-actin (all dilutions 1:1,000) overnight at 4°C. Then, the membranes were washed and incubated with horseradish peroxidase-conjugated (1:1,000) anti-mouse (cat. no. ZB-5305) or (1:1,000) anti-rabbit antibodies (cat. no. ZB-5301; Beijing Zhongshan Golden Bridge Biotechnology Co., Ltd., Beijing, China) at room temperature for 1 h. The protein bands on the membranes were visualized using ECL detection reagents (P0018, BeyoECL Plus; Beyotime Biotechnology, Jiangsu, China). In addition, the antibodies targeting MMP2 and MMP9 (all dilutions 1:1,000) when the cells were treated with matrine (0, 0.4 and 0.8 mg/ml) were tested as described above. ImageJ software was used to perform the densitometric analyses. The experiments were performed in triplicate in three independent experiments.

Actin staining of the cytoskeleton. Huh-7 cells, which were treated with matrine (0, 0.8 mg/ml) were grown on coverslips and fixed with 4% fresh paraformaldehyde for 10 min at room temperature, permeabilized with 0.1% Triton X-100 in PBS for 20 min at room temperature, and then blocked with 5% BSA at room temperature for 1 h. Subsequently, the cells were stained with Phalloidin for 2 h at room temperature in the dark. Following being washed, the cells were counterstained with DAPI for 10 min at room temperature. A fluorescence microscope (Eclipse 90i; Nikon Corporation, Tokyo, Japan) was employed to observe the distribution of filamentous (F)-actin. The assays were performed in triplicate in three independent experiments.

Figure 1. MTT assay demonstrating the cytotoxicity of matrine in hepatocellular carcinoma cells. Huh-7 cells were treated with matrine at concentrations of 0, 0.2, 0.4, 0.8, 1.0, 1.2, 1.4, 1.6, 1.8 and 2.0 mg/ml for 24 and 48 h. Matrine repressed the growth of Huh-7 cells in a dose- and time-dependent manner. The data are presented as the mean ± standard deviation of three independent experiments.

Statistical analysis. Statistical analyses were performed using either the Statistical Program for Social Sciences (SPSS) version 17.0 (SPSS, Inc., Chicago, IL, USA) or the GraphPad Prism software package (v. 4.02; GraphPad, Inc., San Diego, CA, USA). Each experiment was repeated at least three times. The values are expressed as the mean ± standard deviation. Either the Student's t-test or one-way analysis of variance followed by the Newman-Keuls method were performed to analyze the difference between two groups and multiple groups, respectively. P<0.05 was considered to indicate a statistically significant difference.

Results

Matrine inhibits the cell viability of the human hepatoma cell line Huh-7. The effect of various concentrations of matrine (0 to 2 mg/ml) on the cell viability of Huh-7 cells following exposure for 24 or 48 h is demonstrated in Fig. 1. At 1 mg/ml, matrine inhibited the cell viability of Huh-7 cells, whereas at concentrations lower than 1 mg/ml, the inhibitory effect was not marked following 24 h. Therefore, concentrations lower than 1 mg/ml were selected for the experiments associated with invasion and metastasis.

To investigate the long-term effects of matrine on Huh-7 cells proliferation, a colony formation assay was performed. Cells subjected to long-term matrine exposure exhibited significantly reduced colony-forming abilities (P<0.01; Fig. 2). Furthermore, this suppression was more significant in cells exposed to higher concentrations of matrine (P<0.001). These results indicated that a matrine concentration >1 mg/ml exerts a suppressive effect on the proliferative abilities of Huh-7 cells.

Matrine inhibits the migration and invasion of Huh-7 cells. In the present study, the migratory ability of cells treated with matrine was significantly decreased compared with the control Huh-7 cells (P<0.05; Figs. 3 and 4). The results demonstrated that matrine inhibited the invasion and migration of Huh-7 cells in a concentration-dependent manner. In the wound
healing assays, the migration area (%) in the matrine group was significantly increased compared with the control group (P<0.05; Fig. 5). These experiments illustrated that matrine may serve an essential role in regulating the migratory and invasive abilities of a HCC cell line.

Matrine inhibits EMT by suppressing vimentin and enhancing E-cadherin expression in human Huh-7 HCC cells. Vimentin and E-cadherin have been reported to serve important roles in EMT (15). To determine how matrine induces EMT in Huh-7 cells, Huh-7 cells were stimulated with 0.8 mg/ml matrine for 24 h (Fig. 6) and immunofluorescence was used to measure the levels of vimentin and E-cadherin expressed in these cells. It was observed that matrine induced the downregulation of vimentin expression and the upregulation of E-cadherin expression; these results indicate that matrine serves a critical role in reducing EMT by decreasing vimentin expression and increasing E-cadherin expression.

Matrine represses the cancer cells exhibiting an EMT-like phenotypic alteration. Previous studies highlighted EMT as the mechanism by which differentiated epithelial cells undergo notable morphological alterations and acquire more motile and invasive capabilities (16-19). Cytoskeletal reorganization is also a characteristic of EMT and this feature was observed by F-actin staining. As demonstrated in Fig 7A, the stress fibers in Huh-7 cells appeared as lamellipodia and extensive parallel bundles, which were densely stained and exhibited
well-organized structures. In contrast, the lamellipodia disappeared and the parallel bundles were disrupted in the cells treated with matrine, which also demonstrated loosely organized F-actin (Fig. 7B).

Matrine suppresses the expression of Akt/p-Akt, vimentin, MMP2, MMP9, Slug and Snail and increases the expression of PTEN and E-cadherin. Huh-7 cells treated with matrine for 24 h were subjected to a western blotting assay to determine the expression levels of vimentin, MMP2, MMP9, Slug, Snail and E-cadherin. Figs. 8 and 9 revealed that compared with control Huh-7 cells, matrine-treated cells demonstrated significantly increased E-cadherin protein levels (P<0.01) and reduced expression of vimentin, MMP2, MMP9, Slug and Snail in a concentration-dependent manner. The effect of matrine on PTEN and p-Akt expression in Huh-7 cells, was also investigated and the western blot analysis demonstrated that matrine significantly increased PTEN expression and significantly reduced the levels of p-Akt in a concentration-dependent manner (P<0.05; Fig. 10).

Discussion
HCC is the most common liver malignancy and a major health problem worldwide. Surgical resection and liver transplantation, which are the current gold standards for the treatment of HCC, are less than satisfactory due to metastasis and high recurrence...
rates (20). Matrine has been confirmed as a natural anti-tumor agent against several types of cancer, including acute myeloid leukemia, prostate cancer, lung cancer and human hepatoma (21-24). Nevertheless, the anti-metastatic effect of matrine and its associated mechanism(s) in HCC remained unclear. In the present study, matrine was determined to inhibit the mobility and invasive capability of hepatoma cells in vitro by modulating EMT via the activation of the PTEN/Akt pathway. To the best of
the authors' knowledge, this is the first scientific study to report the anti-metastatic effect of matrine on HCC.

In the present study, HCC cell line Huh-7 cells were treated with matrine at concentrations lower than 1 mg/ml, which exerted minimal effects on cell proliferation as confirmed by an MTT assay. Notably, the cell morphology altered and a decrease in lamellipodia, focal adhesion, and the stress fibers in cells following treatment with matrine was observed. Based on this observation, EMT-associated markers were analyzed. As anticipated, the expression levels of mesenchymal markers were reduced and those of epithelial markers were upregulated in the matrine-treated cells. Transwell and wound healing assays were also used to analyze the invasive and migratory abilities of hepatoma cells; these properties were demonstrated to be suppressed. Therefore, these data indicated that matrine may inhibit HCC invasion and metastasis by inducing EMT, which is consistent with other studies that focused on different cancer types (21,22).

Tumor metastasis and recurrence are two of the most difficult challenges in curing hepatoma patients. To fully progress to metastasis, carcinoma cells must complete multiple distinct steps. An important biological process that has been demonstrated to trigger cancer progression, metastasis and recurrence is EMT (25). Indeed, tumor metastasis has been associated with alterations in EMT markers (26), including decreased E-cadherin expression (27), increased MMPs expression (28) increased vimentin expression (29), increased collagen I expression (30), increased fibronectin expression (31) and increased expression of transcription factors from the Snail family (32). The phenomenon of EMT results in epithelial cells losing their cell-cell adhesions, acquiring a mesenchymal phenotype and also losing organized F-actin. This causes cells to become more migratory and invasive, and in the case of tumor cells, the ultimate consequence is metastatic spread (27). In the present study, it was observed that matrine enhanced E-cadherin expression and reduced the expression of vimentin, Slug, Snail, MMP2 and MMP9. The results suggested that the anti-metastatic effect of matrine on HCC is associated with EMT.

EMT refers to a series of phenotypic and molecular alterations that occur in non-cancerous cells over the course of various steps of normal development as well as in cancer cells (33). When EMT develops in cancer, the patient's prognosis may be adversely affected (34). Therefore, an important property of antineoplastic medicine is thought to be the successful repression of EMT (35,36). Several phytochemicals, including matrine, may offer a novel therapeutic approach for treating tumors by repressing EMT (37-40). A previous study demonstrated that the phosphoinositide 3-kinase (PI3K)/Akt pathway serves a significant role in cell growth, metabolism, proliferation, migration and apoptosis (41). Furthermore, p-Akt is a well-known anti-apoptotic protein and the primary downstream kinase of PI3K (42). Accordingly, the p-Akt levels in HCC cells treated with matrine were investigated and the results demonstrated that the p-Akt expression levels were reduced in a concentration-dependent manner. To further clarify the mechanism involved, the upstream regulatory factors of Akt, including PTEN were measured. PTEN is a tumor suppressor protein with protein phosphatase and alkaline phosphatase activity and that can inhibit the PI3K/Akt pathway (43). A previous study confirmed that the p-Akt, p27 and pS6 expression levels were increased in HCC tissues compared with the adjacent non-tumor and normal liver tissues and the normal tissue demonstrated elevated PTEN expression compared with the tumor tissue (44). Furthermore, this previous study demonstrated that over-expression of p-Akt, p27 and pS6 was involved in poor differentiation, vascular invasion and high tumor node metastasis stage of HCC, all of which were also inversely proportional to PTEN expression. A previous study demonstrated that silencing PTEN inhibited the cell growth inhibition and apoptosis induced by matrine in M21 cells (45). These results suggested that PTEN was required for the antitumor efficacy of matrine. In addition, loss of PTEN function is the most commonly known genetic alteration in the PI3-kinase cascade and is commonly associated with B-Raf proto-oncogene mutations (45). Furthermore, in line with recent findings, their results revealed that HCC cells with downregulated p-Akt, p27 and pS6 expression exhibited decreased invasion and metastasis (46). In addition, the induction of EMT by transforming growth factor (TGF)-β is implicated in hepatocarcinogenesis and HCC metastasis. These results demonstrated that upregulation of HAb18G/cluster of differentiation (CD)47 is stimulated by TGF-β and is coupled with the downregulation of E-cadherin and the upregulation of neural-cadherin and vimentin. HAb18G/CD147 expression is controlled by the PI3K/Akt/phosphoinositide 3-kinase (GSK3b) cell survival signaling pathway and is directly regulated by the transcription factor Slug. One study revealed a novel effect of HAb18G/CD47 in mediating EMT during the course of HCC progression and demonstrated that CD47 is a Slug target in the TGF-β-PI3K/Akt-GSK3b-Snail-Slug-CD47 signaling cascade (47). Further experiments are required to confirm the association of the expression of the PTEN/p-Akt and the inhibitory effects of matrine. Therefore, the present study investigated these downstream EMT regulators of the PI3K/Akt pathway and reported that Slug and Slug expression was downregulated in matrine-treated HCC cells. The results demonstrated that the PTEN/PI3K/Akt pathway may serve as an alternative mechanism underlying the effects of matrine.

In conclusion, the present study confirmed the inhibitory function of matrine on the invasive and metastatic abilities of HCC. Furthermore, decreases in vimentin expression and increases in E-cadherin expression induced by matrine are attributed to enhanced PTEN activity and inhibited Akt signaling. This mechanism may contribute to the inhibitory effects of matrine on invasion and metastasis in HCC. These results also revealed a novel potential therapeutic application of matrine as an anti-metastatic therapy for HCC.

Acknowledgements

The authors would like to thank Dr Pan for his helpful advice regarding manuscript preparation. The present study was performed in the First Affiliated Hospital of Harbin Medical University Laboratory and the Shenzhen Longhua District Central Hospital Laboratory.

Funding

No funding was received.
Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Authors' contributions

YWW, BLC and SJZ conceived and designed the research study. YWW, SJZ, JL and BBF performed the experiments and data analysis described. YWW and JY prepared the figures and drafted the manuscript. YWW was a major contributor in writing the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare they have no competing interests.

References

1. Berreta M, Rinaldi L, Di Benedetto F, Llesh A, De Re V, Facchin G, De Paoli P and Di Francia R: Angiogenesis inhibitors for the treatment of hepatocellular carcinoma. Front Pharmacol 7: 428, 2016.

2. Germano D and Daniele B: Systemic therapy of hepatocellular carcinoma: Current status and future perspectives. World J Gastroenterol 20: 3087-3099, 2014.

3. Ingle PV, Samsudin SZ, Chan PQ, Ng MK, Heng LX, Yap SC, Chai AS and Wong AS: Development and novel therapeutics in hepatocellular carcinoma: A review. Ther Clin Risk Manag 12: 445-455, 2016.

4. Knox JJ, Qin R, Strosberg JR, Tan B, Kauhbach A, El-Khoueiry AB, Bekaii-Saab TS, Rousey SR, Chen HX and Erlichman C: A phase II trial of bevacizumab plus temsirolimus in patients with advanced hepatocellular carcinoma. Invest New Drugs 33: 241-246, 2015.

5. Chaffer CL, San Juan BP, Lim E and Weinberg RA: EMT, cell plasticity and metastasis. Cancer Metastasis Rev 35: 645-654, 2016.

6. Zhou SL, Zhou ZJ, Hu ZQ, Li X, Huang XW, Wang Z, Fan J, Dai Z and Zhou J: CXCR2/CXCL5 axis contributes to epithelial-mesenchymal transition of HCC cells through activating PI3K/Akt/GSK-3β signaling. Cancer Lett 358: 124-35, 2016.

7. Darroli AA, Hink MA, DuBuc TQ, Teunisse BJ, Goedhart J, PI3K/Akt/GSK-3β signaling pathways. Acta Pharmacol Sin 38: 120-132, 2017.

8. Wu L, Wang G, Liu S, Wei J, Zhang S, Li and Wang G: Synthesis and biological evaluation of matrine derivatives containing benzo-enpyrone structure as potent anti-lung cancer agents. J Cell Mol Med 21: 1171-1181, 2017

9. Liu Y, Qi Y, Bai ZH, Ni CX, Ren QH, Xu J, Hu HG, Liu L and Li K: Matrine suppresses invasion of castration-resistant prostate cancer cells by downregulating MMP-2/9 via NF-κB signaling pathway. Int J Oncol 50: 25251-25263, 2016.

10. Berreta M, Rinaldi L, Di Benedetto F, Llesh A, De Re V, Facchin G, De Paoli P and Di Francia R: Angiogenesis inhibitors for the treatment of hepatocellular carcinoma. Front Pharmacol 7: 428, 2016.

11. Moretti D, Daniele B: Systemic therapy of hepatocellular carcinoma: Current status and future perspectives. World J Gastroenterol 20: 3087-3099, 2014.

12. Ingle PV, Samsudin SZ, Chan PQ, Ng MK, Heng LX, Yap SC, Chai AS and Wong AS: Development and novel therapeutics in hepatocellular carcinoma: A review. Ther Clin Risk Manag 12: 445-455, 2016.

13. Knox JJ, Qin R, Strosberg JR, Tan B, Kauhbach A, El-Khoueiry AB, Bekaii-Saab TS, Rousey SR, Chen HX and Erlichman C: A phase II trial of bevacizumab plus temsirolimus in patients with advanced hepatocellular carcinoma. Invest New Drugs 33: 241-246, 2015.

14. Chaffer CL, San Juan BP, Lim E and Weinberg RA: EMT, cell plasticity and metastasis. Cancer Metastasis Rev 35: 645-654, 2016.
30. Islam SS, Mokhtari RB, El Hout Y, Azadi MA, Alauddin M, Yeger H and Farhat WA: TGF-β1 induces EMT reprogramming of porcine bladder urothelial cells into collagen producing fibroblasts-like cells in a Smad2/Smad3-dependent manner. J Cell Commun Signal 8: 39-58, 2014.

31. Wu YM, Chen ZJ, Liu H, Wei WD, Lu LL, Yang XL, Liang WT, Liu T, Liu HL, Du J and Wang HS: Inhibition of ERRα suppresses epithelial mesenchymal transition of triple negative breast cancer cells by directly targeting fibronectin. Oncotarget 6: 25588-25601, 2015.

32. Jin Y, Shenoy AK, Doernberg S, Chen H, Luo H, Shen H, Lin T, Tarrash M, Cai Q, Hu X, et al: FBXO11 promotes ubiquitination of the Snail family of transcription factors in cancer progression and epidermal development. Cancer Lett 362: 70-82, 2015.

33. Verdone JE, Parsana P, Veltri RW and Pienta KJ: Epithelial-mesenchymal transition in prostate cancer is associated with quantifiable changes in nuclear structure. Prostate 75: 218-224, 2015.

34. Colangelo T, Fucci A, Votino C, Sabatino L, Pancione M, Laudanna C, Binaschi M, Bigioni M, Maggi CA, Parente D, et al: MicroRNA-130b promotes tumor development and is associated with poor prognosis in colorectal cancer. Neoplasia 15: 1086-1099, 2013.

35. Lv XQ, Qiao XR, Su L and Chen SZ: Honokiol inhibits EMT-mediated motility and migration of human non-small cell lung cancer cells in vitro by targeting c-FLIP. Acta Pharmacol Sin 37: 1574-1586, 2016.

36. Tong D, Liu Q, Liu G, Xu J, Lan W, Jiang Y, Xiao H, Zhang D and Jiang J: Metformin inhibits castration-induced EMT in prostate cancer by repressing COX2/PGE2/STAT3 axis. Cancer Lett 389: 23-32, 2016.

37. Kim EK, Choi EJ and Debnath J: Role of phytochemicals in the inhibition of epithelial-mesenchymal transition in cancer metastasis. Food Funct 7: 3677-3685, 2016.

38. Kaliffatidis G, Hoy JJ and Lokeshwar BL: Bioactive natural products for chemoprevention and treatment of castration-resistant prostate cancer. Semin Cancer Biol 40-41: 160-169, 2016.

39. Murden K, San KK, Martino A and Ezekiel U: The effect of phytochemicals on a chemoresistant, epithelial-mesenchymal transitioned, colorectal cancer cell line. FASEB J 30: 1090.2, 2016.

40. Wang Z, Wu Y, Wang Y, Jin Y, Ma X, Zhang Y and Ren H: Matrine inhibits the invasive properties of human glioma cells by regulating epithelial-to-mesenchymal transition. Mol Med Rep 11: 3682-3686, 2015.

41. Lim W, Yang C, Bazer FW and Song G: Luteolin inhibits proliferation and induces apoptosis of human placental chorionicarcinoma cells by blocking the PI3K/AKT pathway and regulating sterol regulatory element binding protein activity. Biol Reprod 95: 82, 2016.

42. Winnay JN, Solheim MH, Diric E, Sakaguchi M, Noh HL, Kang HJ, Takahashi H, Chudasama KK, Kim JK, Molven A, et al: PI3-kinase mutation linked to insulin and growth factor resistance in vivo. J Clin Invest 126: 1401-1412, 2016.

43. Jing X, Cheng W, Wang S, Li P and He L: Resveratrol induces cell cycle arrest in human gastric cancer MGC803 cells via the PTEN-regulated PI3K/Akt signaling pathway. Oncol Rep 35: 472-478, 2016.

44. Su R, Nan H, Guo H, Ruan Z, Jiang L, Song Y and Nan K: Associations of components of PTEN/AKT/mTOR pathway with cancer stem cell markers and prognostic value of these biomarkers in hepatocellular carcinoma. Hepatol Res 46: 1380-1391, 2016.

45. Jin H, Sun Y, Wang S and Cheng X: Matrine activates PTEN to induce growth inhibition and apoptosis in V600EBRAF harboring melanoma cells. Int J Mol Sci 14: 16040-16057, 2013.

46. Du R, Liu Z, Hou X, Fu G, An N and Wang L: Trichostatin A potentiates genistein-induced apoptosis and reverses EMT in Hep2 cells. Mol Med Rep 13: 5045-5052, 2016.

47. Ru NY, Wu J, Chen ZN and Bian H: HAb18b18G/CD147 is involved in TGF-β-induced epithelial-mesenchymal transition and hepatocellular carcinoma invasion. Cell Biol Int 39: 44-51, 2015.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.